Free Trial
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel
NASDAQ:CELC

Celcuity Q3 2026 Earnings Date & Estimates

Celcuity logo
$69.13 -0.17 (-0.25%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$69.18 +0.05 (+0.07%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celcuity is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Celcuity in Q3 2026

Celcuity is expected to post earnings of -$1.50 per share on revenue of $1.60 million. In the same quarter a year earlier Celcuity reported -$0.92 per share. Celcuity last reported on August 13, 2026, posting -$1.44 per share and missing the -$1.16 consensus estimate. Celcuity has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.50
Expected Revenue
$1.60 million
Prior-Year EPS
-$0.92

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.44 (Missed by -$0.28)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Celcuity Q3 2026 Earnings FAQ

Celcuity (NASDAQ:CELC) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Celcuity's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Celcuity to post earnings of -$1.50 per share for Q3 2026.

The consensus revenue estimate for Celcuity is $1.60 million for Q3 2026.

Celcuity Earnings Headlines

Celcuity: Stronger Clinical Evidence, Much Lower Valuation
October 30 at 7:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4960075-celcuity-stronger-clinical-evidence-much-lower-valuation
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
October 29 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391271/0/en/celcuity-schedules-release-of-third-quarter-2026-financial-results-and-webcast-conference-call.html
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
 |  Porter & Company (Ad)
Will Breast And Prostate Cancer Data Change Celcuity (CELC) Narrative
October 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/breast-prostate-cancer-data-change-201051418.html
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
October 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-study-in-patients-with-hr-her2--advanced-breast-cancer-at-the-esmo-congress-2026-1036661996
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
October 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/24/3387663/0/en/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-study-in-patients-with-hr-her2-advanced-breast-cancer-at-the-esmo-congress-2026.html
See More Celcuity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celcuity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celcuity and other key companies, straight to your email.

About Celcuity

Celcuity (NASDAQ:CELC) is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells. Celcuity uses this platform to develop diagnostic tests and therapeutic-response assays, particularly for use in oncology and in connection with targeted treatments. Its programs have focused on identifying patients whose tumors may respond to specific therapies and supporting the development of potential companion diagnostics for pharmaceutical partners.

Celcuity is headquartered in Minneapolis, Minnesota, and its work is primarily focused on the United States oncology and biopharmaceutical markets. The company was founded in 2012 and is led by Brian Sullivan, who serves as chief executive officer and has been involved in the company’s development of functional cell-based testing technologies.

View Celcuity Profile
Earnings Tools